Payment overview · 2025
General Payments
$889.04
49 reported records · 22 companies
Healthcare provider profile · identity verified
Daniel Boyd Meetze, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPARTANBURG, SC · NPI 1952373060
Verified facts
What the public records show
CMS Open Payments records show Daniel Boyd Meetze, MD received $889.04 in general payments during 2025 across 49 reported records.
PFIZER INC. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $167.33 | 18.8% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $116.85 | 13.1% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.35 | 9.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.03 | 5.7% | 3 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $48.54 | 5.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $45.63 | 5.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $41.91 | 4.7% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.35 | 4.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.17 | 3.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.09 | 3.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $27.90 | 3.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $27.65 | 3.1% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $22.17 | 2.5% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $21.58 | 2.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.99 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.00 | 2.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.07 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.33 | 1.7% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $15.17 | 1.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.13 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.51 | 1.6% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.29 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $889.04 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $101.08 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $97.85 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $83.50 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $66.25 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $66.25 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $66.25 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $61.37 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $51.14 | 3 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $48.54 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $45.63 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $41.91 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.71 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $39.35 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.28 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.17 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.09 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $27.90 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 85 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 254 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 200 | 90 |
| Omeprazole | Omeprazole | 177 | 79 |
| Losartan Potassium | Losartan Potassium | 156 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 66 |
| Lisinopril | Lisinopril | 126 | 55 |
| Gabapentin | Gabapentin | 123 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 50 |
| Prednisone | Prednisone | 98 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 42 |
| Furosemide | Furosemide | 90 | 48 |
| Carvedilol | Carvedilol | 89 | 42 |
| Trazodone Hcl | Trazodone Hcl | 89 | 34 |
| Azithromycin | Azithromycin | 85 | 77 |
| Eliquis | Apixaban | 85 | 23 |
| Tramadol Hcl | Tramadol Hcl | 83 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 31 |
| Metformin Hcl | Metformin Hcl | 76 | 37 |
| Famotidine | Famotidine | 71 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 33 |
| Potassium Chloride | Potassium Chloride | 69 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 23 |
| Montelukast Sodium | Montelukast Sodium | 65 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 20 |
| Alprazolam | Alprazolam | 60 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 54 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 32 |
| Lorazepam | Lorazepam | 48 | 23 |
| Allopurinol | Allopurinol | 46 | 25 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 46 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 21 |
| Irbesartan | Irbesartan | 45 | 21 |
| Simvastatin | Simvastatin | 45 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 17 |
| Celecoxib | Celecoxib | 44 | 25 |
| Sertraline Hcl | Sertraline Hcl | 43 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 17 |
| Cefdinir | Cefdinir | 42 | 37 |
| Clonazepam | Clonazepam | 42 | 15 |
| Pregabalin | Pregabalin | 42 | 15 |
| Alendronate Sodium | Alendronate Sodium | 41 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | suppressed |
| Finasteride | Finasteride | 40 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 19 |
| Meloxicam | Meloxicam | 39 | 16 |
| Baclofen | Baclofen | 37 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 15 |
| Glipizide | Glipizide | 36 | 18 |
| Donepezil Hcl | Donepezil Hcl | 35 | 14 |
| Buspirone Hcl | Buspirone Hcl | 34 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 13 |
| Chlorthalidone | Chlorthalidone | 32 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | 15 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | 11 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 21 |
| Glipizide Er | Glipizide | 25 | 15 |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 21 |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 12 |
| Temazepam | Temazepam | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $889.04 · 49 records | PFIZER INC. | ABRYSVO, ACCRUFER, BREZTRI, CAPLYTA, COMIRNATY, CT THROMBECTOMY SYSTEM KIT, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FLOWTRIEVER CATHETER, S, GEMTESA, INSPIRE, JARDIANCE, Kerendia, Korlym, LINZESS, Leqembi, NEXLETOL, NURTEC ODT, Ozempic, PREVNAR 20, Paradise Ultrasound Renal Denervation System, QULIPTA, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, VIBERZI, Veozah, Wegovy, XYOSTED, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error